Harrow Launches VEVYE® Access for All
Harrow Health, Inc. (HROW)
Last harrow health, inc. earnings: 11/13 04:21 pm
Check Earnings Report
Company Research
Source: Business Wire
Groundbreaking Access Program to Reduce Patient Barriers to Dry Eye Disease Therapy NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today introduced VEVYE® Access for All, a groundbreaking initiative that underscores Harrow’s long-standing commitment to access and affordability. This program, which is now available through our PhilRx specialty pharmacy partner, guarantees access to VEVYE (cyclosporine ophthalmic solution) 0.1% for eligible patients and health plans for $59, ensuring that every patient can affordably start treatment without delay.Key Benefits of the VEVYE Access for All Program:No Prior Authorization Submission Delays for Eligible Patients: Physicians can prescribe VEVYE without frustrating prior authorization paperwork, step edits, and other treatment obstacles.No-Delay Prescription Processing: PhilRx, a Harrow national mail-order pharmacy partner, expedites prescription fulfillment with free home d
Show less
Read more
Impact Snapshot
Event Time:
HROW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HROW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HROW alerts
High impacting Harrow Health, Inc. news events
Weekly update
A roundup of the hottest topics
HROW
News
- How CVS Elevating Vevye To Tier 1 Coverage At Harrow (HROW) Has Changed Its Investment Story [Yahoo! Finance]Yahoo! Finance
- Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS [Seeking Alpha]Seeking Alpha
- Harrow to Present at Two Investor Conferences in DecemberGlobeNewswire
- Harrow Announces Closing of Acquisition of Melt PharmaceuticalsGlobeNewswire
- Harrow (NASDAQ:HROW) had its price target raised by analysts at LADENBURG THALM/SH SH from $64.00 to $66.00. They now have a "buy" rating on the stock.MarketBeat
HROW
Earnings
- 11/10/25 - Beat
HROW
Sec Filings
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- 11/18/25 - Form 8-K
- HROW's page on the SEC website